Record Fourth Quarter and Full Year Performance
Mirion Technologies reported record fourth quarter and full year 2024 performance, with revenue, adjusted EBITDA, and adjusted earnings per share reaching new highs. Adjusted EPS increased from $0.34 to $0.41 per share for the year.
Strong Nuclear Power and Nuclear Medicine Growth
Fourth quarter organic growth was driven by nuclear power (approximately 7%), nuclear medicine (21%), and dosimetry (14%). Full year nuclear power activity was up 8.5%, and nuclear medicine grew by an impressive 7.5%.
Improved Capital Structure
Mirion completed the redemption of outstanding public warrants, repriced its term credit facility, and had all three tranches of founder shares fully vested, resulting in a cleaner capital structure entering 2025.
Expansion in Strategic Partnerships
Mirion signed a strategic alliance with Siemens Healthineers and a partnership agreement with EDF, the largest operator of nuclear power plants, to become an exclusive supplier for new build projects for the next 20 years.
Positive Pipeline and Backlog
The company starts 2025 with 49% of expected revenue already in backlog, up from 46% at the start of 2024, and a healthy pipeline of new order opportunities worth $300 million to $400 million.